View Published SNOMED CT Subset Metadata

QOF Prescribable chronic asthma medication


Subset Name :   
QOF Prescribable chronic asthma medication
Subset Original Id :   
633001000001134
Subset Type :   
Realm Concept

Refset FSN :   
Quality and Outcomes Framework general practice extraction - chronic asthma medication prescribable within general practice simple reference set (foundation metadata concept)
Refset Id :   
12463601000001108
Refset Type :   
Simple

Subset Description :
All VMPs and AMPs associated with the following VTMs: Beclometasone, Orciprenaline, Terbutaline, Aminophylline, Ephedrine, Theophylline, Mometasone, Salbutamol, Salmeterol, Zafirlukast, Budesonide, Ipratropium, Nedocromil, Fluticasone, Montelukast, Sodium cromoglicate + Salbutamol, Bambuterol, Fenoterol, Formoterol, Theophylline + Ephedrine, Omalizumab, Fluticasone + Salmeterol, Budesonide + Formoterol, Ciclesonide, Salbutamol + Ipratropium, Fenoterol + Ipratropium, Salbutamol + Beclometasone, Beclometasone + Formoterol, Fluticasone + Formoterol, Fluticasone + Azelastine, Fluticasone + Vilanterol and Sodium cromoglicate. This subset excludes all the following VMPs and their associated AMPs: Budesonide 3mg gastro-resistant capsules, Budesonide 3 mg gastro-resistant modified release capsules, Budesonide 2mg foam enema, Budesonide 2mg/100ml enema, Budesonide 9mg gastro-resistant granules sachets, Beclometasone 5mg gastro-resistant modified release tablets, Sodium cromoglicate 100mg capsules and Sodium cromoglicate 100mg/5ml oral solution, Budesonide 1mg orodispersible tablets sugar free. The subset also excludes all VMPs and AMPs that have any of the following drug forms: Cream, Ointment, Paint, Nasal spray suspension, Nasal drops, Nasal ointment, Eye drops, Ear drops, Eye ointment, Eye gel, Ear/eye drops solution, Ear/eye/nose drops solution, Spray dose form and Liquid dose form. The subset also specifically excludes AMP concepts with the description AirFluSal Forspiro This subset, as currently published, supports the NHS England QOF business rules for 2016-2017. This subset may contain invalid concepts.

Status

Subset Status :   
Supported
Subset Status Date :   
Feb 5, 2020
Owner (Organisation name) :   
NHS Digital

Purpose and Scope

Usage 1 :

   
Usage Type :    
Intended
Usage Description :    
Intended for secondary uses purposes. Management Information to support counts for establishing Quality and Outcomes Framework points used to determine Practice QOF payments. QOF Indicators Supported: Indicator AST001: The contractor establishes and maintains a register of patients with asthma, excluding patients with asthma who have been prescribed no asthma-related drugs in the preceding 12 months. NICE clinical guidelines & advice: Full NICE guidelines are currently in development with no date currently suggested. NICE Guidelines on asthma diagnosis and monitoring are expected in March 2015. The following NICE evaluations of asthma medication are available: Asthma: fluticasone/formoterol (Flutiform) combination inhaler: https://www.nice.org.uk/advice/esnm3 Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment https://www.nice.org.uk/advice/esnm22 Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler https://www.nice.org.uk/advice/esnm34 Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) https://www.nice.org.uk/advice/esnm53 High dose inhaled corticosteroids in asthma: https://www.nice.org.uk/advice/ktt5 It should be noted that this subset has been built to include only those products that are for the chronic management of asthma and so inhaled products licensed only for use in COPD and adrenaline products are excluded. This means that there is a mismatch between the Read code based business rules and these subsets. This will be resolved before these subsets move to supported status. These subsets are created using the XML format dm+d data and so within these subsets a small number of concepts are inactive (status 2 or 10) in the International Release. The origin of these inactive concepts is the native XML dm+d and they are now inactive in the new International Release due to natural movement and updating of the International Release content. Work is underway to update the dm+d concepts to the new International release identifiers; at this point this mismatch will be resolved. If using the dm+d in SNOMED CT format the International Release relationships will enable migration to the replacement concept. The subsets as published in the current release data are applicable to the QOF year 2017-2017.
Geographic Usage :    
England
Usage Category:    
 Quality Outcome Framework Prescribable


Scope :

   
Inclusion Criteria :   
Age group - any age; Gender - not specified; Sex - not specified
Subject Category :   
Prescribing; Chemicals and Drugs

Publication

Subset Release Category :   
UK Drug Extension
Language :   
en
Folder Name :   
QOF
File Name :   
der1_SubsetMembers_QOFPresChronicAsthmaMed_GB1000001_YYYYMMDD

Subset Licence Type :   
IHTSDO SNOMED CT® Licence; UKTC SNOMED CT® Licence; Open Government Licence

Metadata Version :   
11.0
Last Updated :   
Feb 5, 2020

Related Links

Subset download with descriptions :

UK Drug Extension releases